# Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/chimeric-antigen-receptor-glypican-3-t-cell-therapy-for-advanced-hepatocellular/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Donghua Shi,Yao Shi,Ahmed O. Kaseb,Xingxing Qi,Yuan Zhang,Jiachang Chi,Qing Lü,Huiping Gao,Hua Jiang,Huamao Wang,Daijing Yuan,Hong Ma,Hongyang Wang,Zonghai Li,Bo Zhai |
| Citations | 376 |
| DOI | 10.1158/1078-0432.ccr-19-3259 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3023954831 |
| PMID | 32371538 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Bo Zhai](https://scholariq.org/researchers/bo-zhai/)

## Paper journal

- [Clinical Cancer Research](https://scholariq.org/journals/clinical-cancer-research/)

## Paper primary topic

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Paper topics

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.